Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858942 | 0.91 | KDM4E (0.50) | KDM4EALDH1A1NPSR1RXFP1L3MBTL1 | |
| SCHEMBL4861613 | 0.89 | KDM4E (0.48) | KDM4EALDH1A1NPSR1RXFP1HPGD | |
| SCHEMBL4857021 | 0.89 | KDM4E (0.48) | KDM4EALDH1A1NPSR1RXFP1HPGD | |
| SCHEMBL4855936 | 0.89 | ALDH1A1 (0.48) | KDM4EALDH1A1NPSR1RXFP1HPGD | |
| SCHEMBL2951048 | 0.89 | ALDH1A1 (0.48) | KDM4EALDH1A1NPSR1RXFP1HPGD | |
| SCHEMBL14223879 | 0.88 | PTGS2 (0.39) | PTGS2PTGS1KDM4EALDH1A1NPSR1 | |
| SCHEMBL4855957 | 0.87 | KDM4E (0.47) | PTGS2KDM4EALDH1A1NPSR1RXFP1 | |
| SCHEMBL4854626 | 0.87 | KDM4E (0.47) | PTGS2KDM4EALDH1A1NPSR1RXFP1 | |
| SCHEMBL4858580 | 0.87 | RXFP1 (0.50) | KDM4EALDH1A1NPSR1RXFP1TDP1 | |
| SCHEMBL4853398 | 0.86 | KDM4E (0.43) | KDM4EALDH1A1NPSR1RXFP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | claimed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | claimed |
| US-20030225075-A1 | Novel pyrimidone derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-12-04 | — | — | US | claimed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
| US-20030225075-A1 | Novel pyrimidone derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225075-A1 | Novel pyrimidone derivatives | TPMT, TYMP, TYMS | PTGS2 1692/4885PTGS1 1288/4885KDM4E 4265/4885 |
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | PTGS2 1957/4885PTGS1 1116/4885KDM4E 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.